Cytokines & Growth Factors

Harnessing the Body’s Native Signals for Precision Immunity and Tissue Renewal

Cytokines and growth factors are the biochemical language of the immune system and the architect of repair. Because these signaling proteins trigger cascades that shape inflammation, cytotoxic activity, angiogenesis, and cell differentiation, even subtle changes in sequence, folding, or glycosylation can alter potency or safety. Elise Biopharma has built a dedicated microbial platform that removes that uncertainty. We combine deep synthetic-biology design, data-rich fermentation, and rigorous, regulatory-aligned analytics to carry a cytokine or growth-factor program from plasmid to commercial lot—without detours, without tech-transfer friction, and without compromising speed.

Integrated Molecular Engineering

Every successful cytokine therapy starts with a construct that balances biological firepower and manufacturability. Our discovery-to-feasibility team collaborates with your scientists to translate therapeutic hypotheses into expression-ready DNA:

  • Sequence tailoring for function – Whether you need an IL-2 superkine with enhanced CD8 bias, an IL-15/IL-15Rα fusion that mimics natural trans-presentation, or an anti-inflammatory IL-10 mutein with reduced systemic exposure, we deploy computational protein modeling, alanine-scan libraries, and in-silico immunogenicity prediction to lock in the right amino-acid changes before a single colony is grown.
  • Half-life and targeting add-ons – Albumin-binding domains, XTEN/PASylation tags, and flexible Fc or IgG4 hinge fusions can extend residence time without unwanted effector function; we design linkers and junctions that preserve receptor affinity, then test pharmacokinetics in our CHO-based FcRn binding panel.
  • Host-compatible codon strategies – Proprietary codon-deoptimization for E. coli or rare-tRNA supplementation for Pichia ensures robust transcription yet prevents metabolic burden that often collapses yield in later scale-up.
  • CRISPR host enhancement – If redox balance, secretion, or glycoform editing is critical, we insert or knock out specific oxidoreductases, chaperones, or glycosyltransferases to build a chassis uniquely tuned for your molecule.

Data-Driven Upstream Development

Cytokine expression can swing from milligrams to grams per litre with small changes in induction chemistry or oxygen transfer. Elise solves this by combining high-throughput microscale reactors with digital twins of our 2 000 L production bioreactors:

  • Design-of-Experiments (DoE) screens investigate pH drift, dissolved-oxygen set-points, carbon-nitrogen ratios, and induction temperature in parallel, compressing months of trial-and-error into a two-week matrix.
  • Real-time PAT—Raman spectroscopy for nutrient fingerprinting, capacitance probes for biomass, off-gas mass spectrometry for OUR/CTR—feeds live data into machine-learning models that predict run-end titer within ±5 % by hour six of fermentation.
  • Seamless scale-ladder—5 L glass, 20 L single-use, 200 L stirred-tank, and 2 000 L production vessels share geometric similarity and matched kLa ranges, so process parameters translate without re-tuning. All stages are controlled by the same DeltaV automation layer—so PID loops, alarms, and data historians remain identical from feasibility to GMP.

Robust Downstream Purification

Most cytokines are either tiny, cationic bundles that self-aggregate or complex glycoproteins that shear easily. Elise therefore builds purification trains specific to each biophysical fingerprint:

  • Inclusive inclusion-body refolds—For E. coli–derived payloads, we apply oxidative refolding in arginine–Tris or glutathione-buffer matrices, monitored by intrinsic fluorescence and rapid UPLC to ensure correct disulfide connectivity. We routinely achieve >70 % refold recovery for IL-2, GM-CSF, and IFN-γ.
  • Multimodal capture/polish—Affinity tags (His, Strep, c-Tag) are cleaved in-line with protease columns, followed by cation-exchange or mixed-mode resins that discriminate against host-cell proteins and endotoxin without sacrificing yield.
  • Ultralow endotoxin clearance—Layered depth-filtration and flow-through AEX cut endotoxin to <0.1 EU mg⁻¹ (therapeutic) or <0.05 EU mg⁻¹ (diagnostic). Optional reverse-phase polishing removes LPS charge variants that survive ion exchange.
  • Virus & impurity safety—Although microbial hosts minimize viral risk, low-pH hold and 20 nm nanofiltration steps can be integrated for programs that must align with mammalian-protein viral-clearance expectations.

Formulation, Stability & Fill-Finish

Cytokine potency can evaporate if aggregation, oxidation, or deamidation aren’t managed. Our formulation chemists build stability from the ground up:

  • Buffer and excipient screening across pH 3.5–8, 0–300 mM ionic strength, and a library of surfactants, sugars, and polyols, with DLS, DSC, and turbidity endpoints.
  • High-concentration liquids—formulating viscous IL-2 or GM-CSF at >100 mg mL⁻¹ for sub-cu autoinjectors using arginine-chloride and histidine/polysorbate matrices that hold viscosity to <20 cP.
  • Lyophilization cycles—thermal-analysis-guided freeze profiles with controlled nucleation; our pilot lyos duplicate R&D settings, so scale-up rarely needs a cycle rewrite.
  • Robotic isolator fill-finish—ISO 5 barrier systems perform 100 % weight-verified vials, syringes, or cartridges with container-closure integrity (helium leak) and low oxygen headspace purging for oxidation-prone cytokines.

Analytical & Quality Mastery

Each lot ships with a data-rich Certificate of Analysis that de-risks regulatory review:

  • Potency – validated cell-based STAT-phosphorylation, CTLL-2 proliferation, or bespoke receptor-binding ELISAs calibrated against WHO standards.
  • Identity & purity – intact-mass LC-MS within ±2 Da; SEC-HPLC showing monomer ≥95 %; peptide mapping confirming sequence coverage >98 %.
  • Safety – endotoxin (LAL kinetic chromogenic), residual DNA (qPCR <10 ng mg⁻¹), HCP (platform ELISA <100 ppm).
  • Stability – real-time and accelerated ICH (–80 °C, –20 °C, +5 °C, +25 °C/60 % RH, +40 °C/75 % RH) with monthly potency trending and forced-degradation (light, peroxide, agitation) to map degradation pathways.

All methods are developed and qualified under our Part 11 electronic QMS and can be fully validated—ISO 13485 for IVD enzymes or cGMP for therapeutics—prior to pivotal studies.

Clinical & Commercial Impact

  • Immuno-Oncology: IL-2 muteins and IL-15 complexes activate cytotoxic lymphocytes without IL-2Rα toxicity; Elise supplies Phase I/II lots and later commercial scale.
  • Regenerative Medicine: BMP-7, PDGF-BB, FGF-2 formulated for scaffolds and hydrogels; our high-purity prep eliminates fibroblast-growth-factor degradation fragments that trigger off-target signaling.
  • Vaccine Adjuvants: Low-dose IFN-α and GM-CSF boosts for viral or cancer vaccines; we produce both soluble cytokines and LNP-encapsulated mRNA versions.
  • Diagnostics & Research: ISO 13485 lots of TNF-α, IL-6, and VEGF serve as ELISA calibrators and cell-culture supplements worldwide.

Why Teams Choose Elise for Cytokines & Growth Factors

  1. High titres, low endotoxin – 8–14 g L⁻¹ soluble yields with endotoxin routinely below 0.1 EU mg⁻¹.
  2. Rapid timelines – 6-week feasibility → 3-month pilot → 12-month GMP gene-to-IND path.
  3. Dual compliance – Same facility holds cGMP and ISO 13485 certificates, easing therapeutic–diagnostic crossover.
  4. Data at your fingertips – Live PAT dashboards and weekly digital batch reports keep you audit-ready long before the regulator calls.
  5. No-silo execution – Molecular design, process dev, analytics, and fill-finish teams meet under one roof, removing transfer delays and finger-pointing.

Let’s Signal Progress Together

If your program depends on reliable, bio-potent cytokines or growth factors—delivered on a timeline that matches the science—Elise Biopharma is the partner built for the job.